β3 Adrenergic Receptor Agonist Mirabegron Increases AQP2 and NKCC2 Urinary Excretion in OAB Patients: A Pleiotropic Effect of Interest for Patients with X-Linked Nephrogenic Diabetes Insipidus.

MLA

Milano, Serena, et al. “Β3 Adrenergic Receptor Agonist Mirabegron Increases AQP2 and NKCC2 Urinary Excretion in OAB Patients: A Pleiotropic Effect of Interest for Patients with X-Linked Nephrogenic Diabetes Insipidus.” International Journal of Molecular Sciences, vol. 24, no. 2, Jan. 2023. EBSCOhost, https://doi.org/10.3390/ijms24021136.

APA

Milano, S., Maqoud, F., Rutigliano, M., Saponara, I., Carmosino, M., Gerbino, A., Lucarelli, G., Battaglia, M., Svelto, M., & Procino, G. (2023). β3 Adrenergic Receptor Agonist Mirabegron Increases AQP2 and NKCC2 Urinary Excretion in OAB Patients: A Pleiotropic Effect of Interest for Patients with X-Linked Nephrogenic Diabetes Insipidus. International Journal of Molecular Sciences, 24(2). https://doi.org/10.3390/ijms24021136

Chicago

Milano, Serena, Fatima Maqoud, Monica Rutigliano, Ilenia Saponara, Monica Carmosino, Andrea Gerbino, Giuseppe Lucarelli, Michele Battaglia, Maria Svelto, and Giuseppe Procino. 2023. “Β3 Adrenergic Receptor Agonist Mirabegron Increases AQP2 and NKCC2 Urinary Excretion in OAB Patients: A Pleiotropic Effect of Interest for Patients with X-Linked Nephrogenic Diabetes Insipidus.” International Journal of Molecular Sciences 24 (2). doi:10.3390/ijms24021136.